All In Biotech

Investigational drug · Phase 2

OKI-179

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for RAS Mutation, NRAS Gene Mutation, Melanoma.

Phase 2

Last checked: Nov 19, 2026Latest source record: Mar 7, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

0 still active

All registered trials

2

Any phase or sponsor naming "OKI-179"

First trial start

2022

May 11, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "OKI-179", any sponsor or status.

Conditions studied

As listed on its trial records.

  • RAS Mutation
  • NRAS Gene Mutation
  • Melanoma

Approved drugs for the same conditions: Melanoma · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "OKI-179" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 6 on PubMed

Also in development for RAS Mutation

  • GFH276Phase 25 trials

    Genfleet Therapeutics (Shanghai) Inc. · RAS Mutation, Pancreatic Cancer, Non-small Cell Lung Cancer (NSCLC)

  • TNG462Phase 23 trials

    Tango Therapeutics, Inc. · MTAP-deleted Solid Tumors, Locally Advanced Solid Tumor, PDAC

  • ERAS-0015Phase 21 trial

    Tango Therapeutics, Inc. · PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC

  • vopimetostatPhase 21 trial

    Tango Therapeutics, Inc. · PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.